TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9805361

Group type: EXPERIMENTAL
Intervention: Text-provided elaborations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-generated elaborations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Causally relevant elaborations
Number of subjects: 0
Study: 8608073

Group type: EXPERIMENTAL
Intervention: 3 ml 0.5% plain bupivacaine
Number of subjects: 53

Group type: COMPARATOR
Intervention: 2 ml 0.75% hyperbaric bupivacaine premixed in 8.25% glucose
Number of subjects: 53
Study: 2669036

Group type: EXPERIMENTAL
Intervention: Single dose total body irradiation (STBI) - 10 Gy at a 4.5 cGy/min dose rate, 8 Gy to the lungs
Number of subjects: 54

Group type: COMPARATOR
Intervention: Hyperfractionated total body irradiation (HTBI) - 13.2 Gy in 11 fractions, 3 fractions per day, 9 Gy to the lungs
Number of subjects: 54
Study: 23362

Group type: EXPERIMENTAL
Intervention: 1% selenium disulfid suspension
Number of subjects: 2610

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 2610
Study: 29484551

Group type: EXPERIMENTAL
Intervention: Hypothetico-deduction
Number of subjects: 88

Group type: COMPARATOR
Intervention: Self-explanation
Number of subjects: 88
Study: 27932871

Group type: EXPERIMENTAL
Intervention: FFR-guided therapy
Number of subjects: 220

Group type: COMPARATOR
Intervention: Angiography-guided therapy
Number of subjects: 220
Study: 24978348

Group type: EXPERIMENTAL
Intervention: Social anxiety
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Social anxiety (after controlling for covariates)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Social anxiety (among men)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Social anxiety (among women)
Number of subjects: 580
Study: 23122802

Group type: COMPARATOR
Intervention: Transcatheter Aortic Valve Replacement (TAVR) via transfemoral access (TF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transcatheter Aortic Valve Replacement (TAVR) via transapical access (TA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical Aortic Valve Replacement (AVR)
Number of subjects: 0
Study: 20975109

Group type: EXPERIMENTAL
Intervention: Whey protein and leucine supplementation (19.7 g of whey protein and 6.2 g of leucine)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calorie-equivalent placebo
Number of subjects: 30
Study: 18552703

Group type: EXPERIMENTAL
Intervention: Guanfacine (3 mg/day maximum dose)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 16014407

Group type: EXPERIMENTAL
Intervention: Testosterone 300 microg/d
Number of subjects: 562

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562
Study: 12486924

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 0
Study: 9973009

Group type: EXPERIMENTAL
Intervention: Septal pacing
Number of subjects: 14

Group type: COMPARATOR
Intervention: Apical pacing
Number of subjects: 14
Study: 7481023

Group type: EXPERIMENTAL
Intervention: Group A: Initial dose of 8 ml bupivacaine 0.25% (20 mg) with epinephrine 1/200,000 and 50 micrograms fentanyl followed by continuous infusion of 8 ml/h bupivacaine 0.125% (10 mg/h) with epinephrine 1/400,000
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Group B: Initial dose of 10 ml bupivacaine 0.125% (12.5 mg) with epinephrine 1/400,000 and 50 micrograms fentanyl followed by continuous infusion of 12 ml/h bupivacaine 0.0625% (7.5 mg/h) with epinephrine 1/800,000 and 12 micrograms/h fentanyl
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Group C: Initial dose same as group A, but maintenance through a patient‐controlled (PCA) system with 5 ml bupivacaine 0.25% (12.5 mg) and epinephrine 1/200,000 set for a minimum interval of 1 h
Number of subjects: 101
Study: 2196631

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) at a plasma level of 80 +/- 20 ng/ml, monitored weekly over 8 weeks.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 22419

Group type: EXPERIMENTAL
Intervention: Nabilone (2-mg single doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (5-mg single doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6388971

Group type: EXPERIMENTAL
Intervention: Thymopoietin pentapeptide (TP-5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated T+ and T4+ cells)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (T- B-enriched cells)
Number of subjects: 0
Study: 30999915

Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine (ASMQ) fixed dose combination, 25/55 mg AS/MQ administered once a day for 3 days
Number of subjects: 472
Study: 29880750

Group type: EXPERIMENTAL
Intervention: Glutamine (30 g) with low-nutrient drink (beef soup; 18 kcal)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glutamine (30 g) with high-nutrient drink (75 g dextrose; 255 kcal)
Number of subjects: 8
Study: 27521811

Group type: EXPERIMENTAL
Intervention: Abstinence Reinforcement Therapy (ART) which includes cognitive-behavioral telephone counseling (TC), telemedicine clinic for nicotine replacement (NRT), and mobile contingency management (mCM)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Best practice control consisting of telephone counseling (TC) and telemedicine (NRT)
Number of subjects: 310
Study: 25490675

Group type: EXPERIMENTAL
Intervention: H1/IC31 vaccine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22414157

Group type: EXPERIMENTAL
Intervention: Triamcinolone/demeclocycline (Ledermix)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Calcium hydroxide (Provicol)
Number of subjects: 109
Study: 21162437

Group type: EXPERIMENTAL
Intervention: Aerobic exercise at 60% VO2 peak
Number of subjects: 48

Group type: COMPARATOR
Intervention: Quiet rest (Control)
Number of subjects: 48
Study: 17686832

Group type: EXPERIMENTAL
Intervention: Salba (37 ± 4 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wheat bran
Number of subjects: 20
Study: 15596419

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU, 80 mg bid)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 11983659

Group type: EXPERIMENTAL
Intervention: 0.5 mg x kg(‐1) ketorolac (maximum of 15 mg) six hourly postoperatively for 36 hr
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 0.5 mg x kg(‐1) ketorolac
Number of subjects: 35
Study: 9818634

Group type: EXPERIMENTAL
Intervention: Citalopram 20 or 30 mg/day
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Citalopram 40 or 60 mg/day
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Citalopram 10 or 15 mg/day
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Clomipramine 60 or 90 mg/day
Number of subjects: 475

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study: 7814986

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted (LAC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard laparotomy (SC)
Number of subjects: 42
Study: 2804191

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 4785

Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (50 micrograms in each nostril four times a day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo aerosol preparation identical in appearance
Number of subjects: 35
Study: 31550199

Group type: EXPERIMENTAL
Intervention: Nursing support program in addition to routine nursing care
Number of subjects: 0
Study: 31358032

Group type: EXPERIMENTAL
Intervention: PCT-based algorithm to guide antibiotic use
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study: 28099485

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H5N1 vaccine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unadjuvanted H5N1 vaccine
Number of subjects: 20
Study: 25877784

Group type: EXPERIMENTAL
Intervention: 12-week exercise program (2 supervised gym sessions and 1 home-based session per week)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 147
Study: 24026560

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg/day
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 21333092

Group type: EXPERIMENTAL
Intervention: ECL diode laser‐assisted endonasal DCR without partial anterior middle turbinectomy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Partial anterior middle turbinectomy and ECL diode laser‐assisted endonasal DCR
Number of subjects: 91
Study: 19651918

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 17596795

Group type: EXPERIMENTAL
Intervention: Hib-DPT vaccine (3 doses)
Number of subjects: 2679

Group type: EXPERIMENTAL
Intervention: Hib-DPT vaccine (2 doses)
Number of subjects: 2679

Group type: EXPERIMENTAL
Intervention: Hib-DPT vaccine
Number of subjects: 2679
Study: 15488051

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl and Propofol
Number of subjects: 40
Study: 10924610

Group type: COMPARATOR
Intervention: Autologous buffy coat-reduced RBC transfusions (Group 1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Allogeneic buffy coat-reduced RBC transfusions (Group 2)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: WBC-reduced RBC transfusions (Group 3)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Salvaged blood only (Group 4)
Number of subjects: 44
Study: 8799530

Group type: EXPERIMENTAL
Intervention: 40 mg microenema
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 40 mg orally
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10 mg as a 60 min i.v. continuous infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Suppositories
Number of subjects: 6
Study: 1600971

Group type: EXPERIMENTAL
Intervention: Stepdown regimen of propofol (10 mg kg‐1 h‐1 for 10 min, 8 mg kg‐1 h‐1 for the next 10 min, 6 mg kg‐1 h‐1 thereafter)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Steady rate infusion of propofol (6 mg kg‐1 h‐1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups (Stepdown and Steady rate infusion)
Number of subjects: 44
Study: 2858186

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 45
Study: 31466813

Group type: EXPERIMENTAL
Intervention: NCHT (Neoadjuvant Chemohormonal Therapy)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: NHT (Neoadjuvant Hormonal Therapy)
Number of subjects: 177

Group type: COMPARATOR
Intervention: No-NT (No Neoadjuvant Therapy)
Number of subjects: 177
Study: 29792940

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Spinal mobilization
Number of subjects: 162

Group type: COMPARATOR
Intervention: Sham laser therapy
Number of subjects: 162
Study: 25171552

Group type: EXPERIMENTAL
Intervention: Curcuminoids (1500 mg/day) + piperine (15 mg/day)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 25913052

Group type: EXPERIMENTAL
Intervention: Clean intermittent catheterization (CIC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Triamcinolone ointment CIC
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Contractubex ointment CIC
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 90
Study: 23017624

Group type: EXPERIMENTAL
Intervention: Incremental walking and home-based strength training
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study: 20883592

Group type: EXPERIMENTAL
Intervention: Parent Management Training‐Oregon Model (PMTO™)
Number of subjects: 0
Study: 18697847

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Number of subjects: 885

Group type: COMPARATOR
Intervention: Psycho-educational intervention
Number of subjects: 885
Study: 16868325

Group type: EXPERIMENTAL
Intervention: Nitroglycerin patch (0.2 mg/h)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo group (adhesive patch without active ingredient)
Number of subjects: 22
Study: 12539025

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (150 IU, 3 times a day for 24 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (150 IU, 3 times a day for 48 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10962867

Group type: EXPERIMENTAL
Intervention: Ceftibuten 400 mg od for seven days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ceftriaxone 1 g/day i.v. for a total of 10 days
Number of subjects: 40
Study: 8853769

Group type: EXPERIMENTAL
Intervention: Amoxycillin suspension given pre-prandially
Number of subjects: 79

Group type: COMPARATOR
Intervention: Amoxycillin suspension given post-prandially
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Good compliance group
Number of subjects: 79

Group type: COMPARATOR
Intervention: Others completing the protocol
Number of subjects: 79
Study: 1377333

Group type: EXPERIMENTAL
Intervention: Paracetamol (3 x 1000 mg over 8 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6725527

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg orally)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg orally) plus Bromocriptine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Domperidone (20 mg orally) plus Bromocriptine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31106714

Group type: EXPERIMENTAL
Intervention: Automated hand hygiene monitoring system (AHHMS) with supplementary strategies
Number of subjects: 93

Group type: COMPARATOR
Intervention: Automated hand hygiene monitoring system (AHHMS) without supplementary activities
Number of subjects: 93

Group type: COMPARATOR
Intervention: Non-Clostridioides difficile HAIs
Number of subjects: 93

Group type: COMPARATOR
Intervention: Clostridioides difficile infections
Number of subjects: 93
Study: 30012049

Group type: EXPERIMENTAL
Intervention: Collagenase injection
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Needle fasciotomy
Number of subjects: 93
Study: 27452767

Group type: EXPERIMENTAL
Intervention: CPAP withdrawal for 2 weeks
Number of subjects: 149

Group type: COMPARATOR
Intervention: CPAP continuation for 2 weeks
Number of subjects: 149
Study: 23861153

Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy (WBRT) alone
Number of subjects: 176
Study: 22388713

Group type: EXPERIMENTAL
Intervention: Head orthesis therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (infants without head deformities)
Number of subjects: 40
Study: 19998218

Group type: EXPERIMENTAL
Intervention: EUS-cytobrushing
Number of subjects: 37

Group type: COMPARATOR
Intervention: EUS-FNA
Number of subjects: 37
Study: 18693659

Group type: EXPERIMENTAL
Intervention: Fentanyl (25 microg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Bupivacaine (2.5 mg)
Number of subjects: 64
Study: 15960717

Group type: EXPERIMENTAL
Intervention: Bonfils intubation fibrescope
Number of subjects: 20

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 20
Study: 12566364

Group type: EXPERIMENTAL
Intervention: IVUS-guided percutaneous transluminal coronary angioplasty (aggressive PTCA)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 254
Study: 10548188

Group type: EXPERIMENTAL
Intervention: Plasmafiltration (PF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 8517061

Group type: EXPERIMENTAL
Intervention: 2 g vigabatrin for 2 months
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: titrated optimal dosage vigabatrin for another 2 months
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: EEG mapping after 2 months vigabatrin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ERP mapping after 2 months vigabatrin
Number of subjects: 10
Study: 3481814

Group type: EXPERIMENTAL
Intervention: Angiotensin II (ANG II) infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of ANG II and NA infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study: 31736269

Group type: COMPARATOR
Intervention: Dexamethasone implant (Ozurdex)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ranibizumab (Lucentis)
Number of subjects: 18
Study: 29164797

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (LCZ696) 200 mg twice per day, initiated and up-titrated over 3 or 6 weeks
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Gradual up-titration (6 weeks) of sacubitril/valsartan
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (LCZ696) 200 mg twice per day
Number of subjects: 498
Study: 27595023

Group type: EXPERIMENTAL
Intervention: Home visiting program 1
Number of subjects: 82

Group type: COMPARATOR
Intervention: Home visiting program 2
Number of subjects: 82
Study: 25618791

Group type: EXPERIMENTAL
Intervention: 300 kcal/day (MOD)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 600 kcal/day (HIGH)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 53
Study: 24022747

Group type: EXPERIMENTAL
Intervention: Methotrexate and intraarticular glucocorticoids plus adalimumab
Number of subjects: 180

Group type: COMPARATOR
Intervention: Methotrexate and intraarticular glucocorticoids plus placebo/adalimumab
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Baseline M-ficolin level in the lowest quartile
Number of subjects: 180
Study: 21511212

Group type: EXPERIMENTAL
Intervention: High frequency rTMS delivered to the left dorsolateral prefrontal cortex
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 38
Study: 19366965

Group type: EXPERIMENTAL
Intervention: Ranirestat 20 mg/day
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Ranirestat 40 mg/day
Number of subjects: 549

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study: 16935343

Group type: EXPERIMENTAL
Intervention: 16-cobalt gray equivalent (CGE) proton radiation
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 24-cobalt gray equivalent (CGE) proton radiation
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison between the two doses)
Number of subjects: 166
Study: 15293170

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) applied for at least six hours per day in addition to standard COPD treatment.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard COPD treatment (Control group).
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: NIV (Intervention group).
Number of subjects: 300
Study: 11739062

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10584721

Group type: EXPERIMENTAL
Intervention: Semirecumbent body position
Number of subjects: 86

Group type: COMPARATOR
Intervention: Supine body position
Number of subjects: 86
Study: 8004320

Group type: EXPERIMENTAL
Intervention: n‐CPAP (mouth closed)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: face mask CPAP (f‐CPAP)
Number of subjects: 6
Study: 2813482

Group type: EXPERIMENTAL
Intervention: Cocaine infusion after bolus loading doses
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo infusion after bolus loading doses
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cocaine infusion
Number of subjects: 7
Study: 4586044

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (400 mug daily, intranasally)
Number of subjects: 29
Study: 31579978

Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of Silymarin and Doxycycline
Number of subjects: 60
Study: 28735067

Group type: EXPERIMENTAL
Intervention: irinotecan/cetuximab followed by FOLFOX-4 (arm A)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: FOLFOX-4 followed by irinotecan/cetuximab (arm B)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (arm A)
Number of subjects: 110
Study: 25327537

Group type: EXPERIMENTAL
Intervention: Tapered implants (test group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cylindrical implants (control group)
Number of subjects: 10
Study: 23234265

Group type: EXPERIMENTAL
Intervention: Static stretching of the quadriceps muscle (knee flexion) for three sets of 30 seconds with 30 seconds rest intervals
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no stretching)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Static stretching of the quadriceps muscle
Number of subjects: 27
Study: 21505349

Group type: EXPERIMENTAL
Intervention: LOS100 (Losartan 100 mg q.d.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LOS200 (Losartan 100 mg b.i.d.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LOS100 + LIS20 (Losartan 100 mg q.d. + Lisinopril 20 mg q.d.)
Number of subjects: 20
Study: 18259807

Group type: EXPERIMENTAL
Intervention: Video-assisted thyroidectomy (VAT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional thyroidectomy (CT)
Number of subjects: 65
Study: 17224949

Group type: EXPERIMENTAL
Intervention: Topical 2% cyclosporine A in preservative-free artificial tears
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 20
Study: 14499682

Group type: EXPERIMENTAL
Intervention: 0.5mg dutasteride and 0.4mg tamsulosin for 24 weeks followed by dutasteride and tamsulosin matched placebo for the remaining 12 weeks (DT24+D12)
Number of subjects: 327

Group type: COMPARATOR
Intervention: 0.5mg dutasteride and 0.4mg tamsulosin for 36 weeks (DT36)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: 0.5mg dutasteride and 0.4mg tamsulosin for 24 weeks followed by dutasteride monotherapy
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Withdrawal of tamsulosin therapy at week 24
Number of subjects: 327